Mercy Places First Commercial Eversense 365: The World’s First and Only 365-Day Continuous Glucose Monitor
Senseonics Holdings, Inc. announced that its Eversense 365 continuous glucose monitoring (iCGM) system has been approved in the U.S. for adults with Type 1 and Type 2 diabetes. This next-generation system, now commercially launched by Ascensia Diabetes Care, allows for one year of continuous glucose monitoring with minimal interruptions, requiring only one calibration per week and no additional sensor replacements. The first patient to receive the Eversense 365 system is part of a collaboration with Mercy, a major healthcare provider, which expects about 30,000 of its patients could benefit from this technology. Senseonics and Mercy expect this significant breakthrough in diabetes technology and management to improve glycemic control for patients, reduce distress associated with managing diabetes and lower overall healthcare costs for providers and payers.
#cgm
#institution